Pfizer's Paxlovid Shows 26% Reduction in Long COVID Risk, Highlights from Recent Preprint Study

Recently, a preprint paper was publishedResearch on the Risk of Post-COVID Conditions with Paxlovid.

The study indicated that,During the period of COVID-19 infection, taking Paxlovid can significantly reduce the risk of post-COVID conditions.

Specifically, the risk of PASC was reduced by 26%, the risk of post-acute death was reduced by 48%, and the risk of post-acute hospitalization was reduced by 30%.

This study used the healthcare database of the U.S. Department of Veterans Affairs to identify health system users who tested positive for SARS-CoV-2 between March 1, 2022, and June 30, 2022, were not hospitalized on the day of their positive test, had at least one risk factor for progression to severe COVID-19 disease, and survived within the first 30 days following their SARS-CoV-2 diagnosis.

People who received oral nirmatrelvir treatment within 5 days after testing positive (n = 9,217) and those who did not receive COVID-19 antiviral or antibody treatment during the acute phase of SARS-CoV-2 infection (control group, n = 47,123).

Compared with the control group, nirmatrelvir treatment was associated with a reduced risk of PASC (HR 0.74 95%CI (0.69, 0.81), ARR 2.32 (1.73, 2.91)), including a reduction in 10 of the 12 acute sequelae of the cardiovascular system (arrhythmia and ischemic heart disease), coagulation and hematological disorders (deep vein thrombosis and pulmonary embolism), fatigue, liver disease, acute kidney disease, myalgia, neurocognitive impairment, and shortness of breath. Nirmatrelvir was also associated with a reduced risk of post-acute mortality (HR 0.52 (0.35, 0.77), ARR 0.28 (0.14, 0.41)) and post-acute hospitalization (HR 0.70 (0.61, 0.80), ARR 1.09 (0.72, 1.46)).

Long COVID — the condition that includes post-acute sequelae of SARS-CoV-2 (PASC) — affects millions of people worldwide. Preventing PASC is an urgent public health priority.

Editor: Dadasiva

Disclaimer: This article is a reprint from Pharma Intelligence Network. The images and text are owned by the original author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will delete it as soon as possible.